Miraculins Completes Share Consolidation

Miraculins Completes Share Consolidation 
WINNIPEG, MANITOBA -- (Marketwired) -- 01/24/14 --   Miraculins Inc.
(TSX VENTURE: MOM) ("Miraculins" or the "Company"), a medical
diagnostic company focused on acquiring, developing and
commercializing diagnostic and risk assessment technologies for unmet
clinical needs, announces that, further to its news release of
January 13, 2014, the TSX Venture Exchange has approved the
consolidation of the Company's issued and outstanding common shares
("Common Shares") on the basis of ten pre-consolidation Common Shares
for every one post-consolidation Common Share and the Company has
proceeded with the consolidation. Effective at the opening of the
market on January 27, 2014, Miraculins' shares will commence trading
on the TSX Venture Exchange on a consolidated basis under the new
CUSIP number 60462L207. The Company's name and trading symbol will
not change as a result of the consolidation. The Company will have
approximately 12,492,010 Common Shares issued and outstanding as a
result of the consolidation. Letters of transmittal with respect to
the consolidation will be sent to registered shareholders by CST
Trust Company, the Company's Transfer Agent. 
About Miraculins Inc. 
Miraculins is a medical diagnostic company focused on acquiring,
developing and commercializing non-invasive technologies for unmet
clinical needs. A significant number of promising diagnostic
opportunities remain un-commercialized because of the sizable gap
between the discovery stage, when research institutions are typically
involved, and the commercialization stage, when the larger commercial
enterprises become interested. Miraculins has direct experience in
bridging this gap. The Company's PreVu(R) POC Test is a revolutionary
new coronary artery disease risk assessment technology that measures
cholesterol levels in a patient's skin non-invasively, painlessly and
without the need for fasting. The Company's Scout DS(R) system is the
first non-invasive diabetes testing system designed to provide a
highly sensitive and convenient method for measuring diabetes related
biomarkers in the skin, the accumulation of which are accelerated by
abnormal blood sugar levels and oxidative stress. Unlike current
testing methods, a Scout DS(R) test requires no blood draw, no
fasting, and no waiting for a lab result. The product has been used
and validated in thousands of patients around the world. The
Company's preeclampsia program is partnered with Alere Inc., one of
the world's largest diagnostic companies. For more information visit
www.miraculins.com. 
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.  
PreVu(R) and SCOUT DS(R) are registered trademarks of Miraculins Inc.
All Rights Reserved. 2014. 
Contacts:
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)
info@miraculins.com
www.miraculins.com
 
 
Press spacebar to pause and continue. Press esc to stop.